| Literature DB >> 33174955 |
Luciano Freitas Fernandes1,2, Geziella Áurea Aparecida Damasceno Souza3, Anna Christina de Almeida3, Léia Cardoso4, Mauro Aparecido de Sousa Xavier4, Talles Patrick Prates Pinheiro4, Guilherme Henrique Santos da Cruz2, Hellen Fonseca Silva Dourado2, Wender Soares Silva5, Alessandra Rejane Ericsson de Oliveira Xavier4.
Abstract
INTRODUCTION: Contaminated hospital environments contribute to the transmission of microorganisms associated with healthcare. Contaminated surfaces handled by patients or healthcare professionals are a source of microorganism transmission by hand. Methicillin-resistant Staphylococcus bacteria are among the main agents responsible for increasing healthcare-associated infections in Brazil and worldwide.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33174955 PMCID: PMC7670759 DOI: 10.1590/0037-8682-0244-2020
Source DB: PubMed Journal: Rev Soc Bras Med Trop ISSN: 0037-8682 Impact factor: 1.581
FIGURE 1:Sampling sites in an ICU. The arrows indicate the sampling locations: infusion pump keypad (PK), left side rail (LS), right side rail (RS), cardiac monitor (CM) and bedside table (BT).
FIGURE 2:Result of the total viable count of microorganisms sampled on different surfaces in the intensive care unit rooms.
Identification and characterization of the phenotypic antimicrobial resistance profile of microorganisms isolated from bed surfaces of an Intensive Care Unit in a hospital in Southeastern Brazil.
| Nº | Location site | Gene | Gene | Proteomic identification | Phenotypic antimicrobial resistance profile |
|---|---|---|---|---|---|
| femA | mecA | MALDI-TOF | |||
| 1 | Right side rail - Bed 1 | - | + |
| OXA; ERI; CFO; CRX; SUT; AMI; CLI; GEN |
| 2 | Left side rail - Bed 1 | - | + |
| OXA; ERI; CFO; CRX; SUT; AMI; CLI; GEN |
| 3 | Bedside table - Bed 1 | - | + |
| OXA; ERI; CFO; CIP; CRX; AMI; CLI; GEN |
| 4 | Pump keypad - Bed 1 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CLI; GEN |
| 5 | Cardiac monitor - Bed 1 | - | + |
| OXA; ERI; CFO; CFZ; CIP; SUT; CRX; CLI |
| 6 | Right side rail - Bed 2 | - | - |
| OXA; CFO; CFZ; CRX; SUT; AMI; CLI |
| 7 | Left side rail - Bed 2 | - | + |
| OXA; ERI; CFO; SUT; AMI; CLI; GEN |
| 8 | Bedside table - Bed 2 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CLI; GEN. |
| 9 | Pump keypad - Bed 2 | - | + |
| OXA; ERI; CFO; CRX; SUT; AMI; CLI; GEN |
| 10 | Cardiac monitor - Bed 2 | - | + |
| OXA; ERI; CFO; CRX; SUT; AMI; CLI; GEN |
| 11 | Right side rail - Bed 3 | - | - |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 12 | Left side rail - Bed 3 | - | - |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 13 | Right side rail - Bed 4 | - | + |
| OXA; ERI; CFO; CRX; CIP; AMI; CLI; GEN |
| 14 | Left side rail - Bed 4 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; AMI; CLI; GEN |
| 15 | Bedside table - Bed 4 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 16 | Pump keypad - Bed 4 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; AMI; CLI |
| 17 | Cardiac monitor - Bed 4 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 18 | Right side rail - Bed 5 | - | + |
| OXA; ERI; CFO; CRX; CIP; AMI; CLI; |
| 19 | Left side rail - Bed 5 | - | + |
| OXA; ERI; CFO; CFZ; CRX; SUT; AMI; CLI; GEN |
| 20 | Bed side table - Bed 5 | - | + |
| OXA; ERI; CFO; AMI; CLI; GEN |
| 21 | Pump keypad - Bed 5 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 22 | Cardiac monitor - Bed 5 | - | - |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 23 | Right side rail - Bed 6 | - | + |
| OXA; ERI; CFO; CRX; SUT; AMI; CLI; GEN |
| 24 | Left side rail - Bed 6 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; AMI; CLI; CFL; GEN |
| 25 | Bedside table - Bed 6 | - | + |
| OXA; ERI; CFO; CFZ; CIP; SUT; AMI; CLI; CFL; GEN |
| 26 | Pump keypad - Bed 6 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; AMI; CLI; CFL; GEN |
| 27 | Cardiac monitor - Bed 6 | - | + |
| OXA; ERI; CFO; CRX; CIP; SUT; AMI; CLI; GEN |
| 28 | Right side rail - Bed 7 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; |
| 29 | Left side rail - Bed 7 | - | + |
| OXA; ERI; CFO; CRX; SUT; AMI; CLI; GEN |
| 30 | Pump keypad - Bed 7 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 31 | Cardiac monitor - Bed 7 | - | + |
| OXA; ERI; CFO; CRX; SUT; AMI; CLI; GEN |
| 32 | Right side rail - Bed 8 | - | + |
| OXA; ERI; CFO; CRX; SUT; AMI; CLI; GEN |
| 33 | Left side rail - Bed 8 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; AMI; CLI; GEN |
| 34 | Bedside table - Bed 8 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; GEN |
| 35 | Cardiac monitor - Bed 8 | - | + |
| OXA; ERI; CFO; CRX; SUT; AMI; CLI; GEN |
| 36 | Right side rail - Bed 9 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 37 | Left side rail - Bed 9 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 38 | Pump keypad - Bed 9 | - | + |
| OXA; ERI; CFO; CFZ; CRX; SUT; CLI; CFL; |
| 39 | Cardiac monitor - Bed 9 | - | + |
| OXA; ERI; CFO; CFZ; CRX; CIP; SUT; CLI; CFL; GEN |
| 40 | Left side rail - Bed 10 | - | + |
| OXA; ERI; CFO; CFZ; CRX; SUT; AMI; CLI; CFL; GEN |
| 41 | Bedside table - Bed 10 | - | + |
| OXA; ERI; CFO; SUT; CLI; GEN |
| 42 | Cardiac monitor - Bed 10 | - | + |
| OXA; ERI; CFO; CRX; CIP; AMI; CLI; GEN |
OXA: Oxacillin; ERI: Erythromycin; CFO: Cefoxitin; CFZ: Cefazolin; CRX: cefuroxime; CIP: Ciprofloxacin; SUT: sulfatrim; AMI: amikacin; CLI: clindamycin; CFL: cephalothin; GEN: gentamicin.
FIGURE 3:Result of PCR analysis to detect femA and mecA genes among Staphylococcus isolated from different surfaces of an ICU bed. Panel A. Standardization of the PCR for detection of femA and mecA genes in standard strains of Staphylococcus aureus. Line 1: Mid-Range DNA Ladder molecular weight marker (Cellco Biotechnology); Lines 2 to 4: Amplification of the femA gene in standard strains of S.aureus ATCC 43300, S. aureus ATCC 29230, and S. aureus 25923. Lines 5 and 6: negative and positive controls, respectively, for the PCR of the mecA gene in strains of S. aureus ATCC 29230 and S.aureus ATCC 43300. Panel B. Result of PCR analysis for detection of the mecA gene among the isolated Staphylococcus. Line 1: Mid-Range DNA Ladder molecular weight marker (Cellco Biotechnology); Lines 2 to 12: Amplification of the mecA gene in isolates 32 to 42.
Antimicrobial resistance profile tested for each species identified by MALDI-TOF.
| Quantity | OXA | ERI | CFO | CFZ | CRX | CIP | SUT | AMI | CLI | CFL | GEN | Total Resistant | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 23 (55%) | 23 | 23 | 23 | 10 | 17 | 7 | 16 | 15 | 22 | 5 | 21 | 182 |
|
| 11 (26.2%) | 11 | 10 | 11 | 10 | 11 | 9 | 10 | 3 | 11 | 9 | 10 | 105 |
|
| 4 (9.5%) | 4 | 4 | 4 | 1 | 3 | 3 | 2 | 4 | 4 | 0 | 3 | 32 |
|
| 2 (4.8%) | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 2 | 18 |
|
| 1 (2.4%) | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 7 |
|
| 1 (2.4%) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 8 |
| Total resistant | 42 | 41 | 42 | 25 | 34 | 21 | 31 | 24 | 41 | 15 | 36 | 352 |
OXA: Oxacillin; ERI: Erythromycin; CFO: Cefoxitin; CFZ: Cefazolin; CRX: cefuroxime; CIP: Ciprofloxacin; SUT: sulfatrim; AMI: amikacin; CLI: clindamycin; CFL: cephalothin; GEN: gentamicin.